The C-terminal tail of the calcium receptor (CaR) regulates the affinity of the receptor for ligand, desensitization, and membrane localization. To determine the role of specific amino acids in the bovine parathyroid CaR in mediating signal transduction and cell-surface expression, we transfected truncated and mutated CaR cDNAs into HEK-293 cells. ] o -induced InsP production. The levels of expression and glycosylation of these mutants were comparable with wild-type CaRs, but both receptors were profoundly retained in intracellular organelles and co-localized with the endoplasmic reticulum marker BiP. This suggested that the signaling defects of these receptors were likely because of defective trafficking of receptors to the cell surface. Modeling of the C-terminal domain of the CaR indicated that His 880 and Phe 882 are situated in a putative ␣-helical structure of 15 amino acids between residues 877 and 891 in the C-terminal tail. Our studies support the idea that specific amino acids, and possibly a unique secondary structure in the C-terminal tail, are required for the efficient targeting of the CaR to the cell surface required for PLC activation.
. These receptors belong to family C of the G protein-coupled receptor superfamily. In response to high [Ca 2ϩ ] o or a variety of polyvalent cations, CaRs activate phospholipase C (PLC), inhibit cyclic AMP formation, and open nonselective cation channels in parathyroid cells and in heterologous expression systems (1) (2) (3) (4) . Like other G protein-coupled receptors in family C, metabotropic glutamate receptors (5, 6) , the ␥-aminobutyric acid receptor-B (7), and a large group of pheromone receptors (8, 9) , the bovine parathyroid CaR has a large N-terminal extracellular domain (613 amino acids) and C-terminal tail (222 amino acids). Functional properties are beginning to be ascribed to specific domains of the CaR.
Considerable insights regarding the structure-function properties of the CaR have resulted from studying naturally occurring receptor mutants in kindreds with familial hypocalciuric hypercalcemia (FHH) and autosomal dominant hypocalcemia (10) . These studies strongly support the idea that the amino acids in the N-terminal extracellular domain of the CaR directly or indirectly participate in binding of Ca 2ϩ or other cationic agonists to the receptor and in determining receptor sensitivity to ligand. (10) . Studies in vitro on the biochemical properties of loss-of-function mutations in the CaR, in combination with receptor mutagenesis, indicate that specific residues in the second and third intracellular loops of the CaR are critical for PLC activation and efficient cell-surface expression (11) .
Studies of C-terminally truncated CaRs indicate that most of the amino acids in the tail of the receptor are not directly involved in PLC activation and intracellular Ca 2ϩ mobilization (12) (13) (14) . This work, however, further suggests that a discrete domain in the tail (residues 874 -888 and a specific Thr residue) is important in modulating receptor expression, signal transduction, and desensitization (12) (13) (14) .
The importance of the C-terminal tail of the CaR to parathyroid function is highlighted by studies of patients with FHH and neonatal severe hyperparathyroidism (NSHPT) who have mutations in this region. In one kindred, an Alu-repetitive insertion was found in their CaR genes at residue 876 (13) . This results in a receptor protein that terminates at amino acid 876 but to which is added a non-CaR peptide, Gln-Leu-Thr-Leu-Ser plus 29 Phe residues, encoded by the inserted Alu sequence. When CaR cDNA with the same Alu insertion is expressed in HEK-293 cells, the ability of high [Ca 2ϩ ] o to raise intracellular [Ca 2ϩ ] is significantly impaired (to 10% or less of the wt CaR) (13) . In an unusual kindred with features of both FHH and primary hyperparathyroidism, mutation of Phe 881 (Phe 882 in the bovine CaR) to Leu in the C-terminal tail results in defective signal transduction (15) . In HEK-293 cells, this mutant receptor shows reduced intracellular Ca 2ϩ responses to high [Ca 2ϩ ] o (15) . Finally, a family reported with a large deletion in the tail of the CaR (amino acids 895-1075) has autosomal dominant hypocalcemia indicating a gain-of-function (16) . When expressed in HEK-293 cells, this mutant CaR demonstrates enhanced cell-surface expression and increased sensitivity to high [Ca 2ϩ ] o (16) . Overall, this work supports the importance of the tail of the CaR and accentuates its diverse roles.
The present studies were undertaken to identify residues in the tail of the CaR involved in regulating receptor expression and coupling to signaling pathways. Our results demonstrated that His 880 and Phe 882 , in a putative ␣-helical domain in the C-terminal tail of the CaR, are important for the efficient targeting of the receptor to the cell surface. Mutations of these residues and or their deletion cause intracellular retention of the receptor and reduced PLC activation.
EXPERIMENTAL PROCEDURES
Materials-The bovine parathyroid CaR cDNA (1) was provided by Dr. Edward Brown (Harvard Medical School, Boston). The Chameleon double-stranded, site-directed mutagenesis kit and pBluescript II SKϪ (pBS) were obtained from Stratagene (La Jolla, CA). pcDNA1/Amp and pCEP4 were purchased from Invitrogen (Carlsbad, CA). Restriction enzymes were from Stratagene (La Jolla, CA), Life Technologies, Inc., and Promega (Madison, WI). Rabbit anti-CaR antisera (21825A and 321113A) were raised against an extracellular and intracellular epitope of the bovine parathyroid CaR, respectively, and affinity-purified as described (3) . Mouse anti-Grp78 (BiP) was purchased from StressGen Biotechnologies Corp (Victoria, British Columbia, Canada). Rat anti-CD44 was developed and characterized previously (17, 18) . Fluoresceinconjugated goat anti-rabbit IgG and Texas Red-conjugated goat anti-rat or -mouse IgG for immunocytochemistry were obtained from Molecular Probes, Inc. (Eugene, OR). Endoglycosidase H (Endo-H) and peptide N-glycosidase F (PNG-F) were purchased from New England Biolabs (Beverly, MA) and Roche Molecular Biochemicals, respectively. Other supplies were from previously noted sources (3, 11, 19) .
Mutagenesis and Subcloning of CaR cDNAs-The truncated CaR cDNAs (CaR-(1-866)/pGEM-HE, CaR-(1-895)/pGEM-HE, and CaR-(1-929)/pGEM-HE) (Fig. 1a) were made by ligating PCR-generated fragments with premature stop codons inserted after the residues Ser 866 , Val 895 , and Gln 929 , respectively, into wt CaR/pGEM-HE DNA. The wt CaR/pGEM-HE was constructed as described previously (3) and used as the template in PCR reactions to generate truncated CaR cDNA fragments. The upper primer used in PCRs is derived from a sequence (5Ј-TGCAGATTGTCATCTGTGCC-3Ј) at the 5Ј-end of a unique XhoI site (nucleotide 2762) in the bovine parathyroid CaR cDNA. The three lower primers were derived from the sequences flanking the corresponding truncation sites (T-866, 5Ј-TGGTCTAGAGTCAGGAAGGCT-TGAAGAGGATGAT-3Ј; T895, 5Ј-TGGTCTAGAGTCAGACGTTGCTG-CGGCGCAGCGT-3Ј; and T929, 5Ј-TGGTCTAGAGTCACTGCTGCTG-AGGGAACGGGT-3Ј) . Each of these primers introduces a stop codon and XbaI site at the 3Ј-end of the construct. After digestion with XhoI and XbaI, PCR fragments were ligated into wt CaR/pGEM-HE (3, 11, 20) . Tandem-alanine (TA) and single-site mutant receptors in the background of wt CaR/pBS and CaR-(1-895)/pBS were made by PCR or site-directed mutagenesis using the Chameleon kit according to the manufacturer's instructions. Mutations were confirmed by automated DNA sequencing (Biomolecular Resource Center, University of California, San Francisco). Wt CaR/pBS was generated by ligating an SmaI fragment (nucleotides 248 -3819) of the bovine parathyroid CaR cDNA into pBS (11) . CaR-(1-895)/pBS was constructed by ligating an XhoI/XbaI fragment from CaR-(1-895)/pGEM-HE into precut wt CaR/pBS containing the rest of the receptor (11, 20 Immunoblotting and Immunocytochemistry-Crude membrane protein fractions were prepared from HEK-293 cells, electrophoresed on SDS-PAGE gels, and transferred to nitrocellulose membranes as detailed previously (3, 19) . Membranes were blotted with one of two affinity-purified rabbit antisera (21825B (50 nM) or 321113A (10 nM)) (3, 11, 22) . Signal detection was by the enhanced chemiluminescence (ECL TM ) assay kit (Amersham Pharmacia Biotech). CaR protein expression in membrane protein fractions prepared from cells expressing wt and expressing mutant CaRs constructs was assessed by immunoblotting in at least two independent experiments.
In studies of receptor glycosylation, crude membrane protein fractions were digested with PNG-F or Endo-H as described (23) . For experiments with Endo-H, membrane proteins (10 g) were denatured in a solution containing SDS (0.05%, w/v) and 2-mercaptoethanol (50 mM) at 37°C for 15 min. After adding Endo-H (500 units), NaOAc (70 mM; pH 5.2), and Triton X-100 (0.8%, v/v), proteins were further incubated at 37°C for 1 h. For PNG-F digestion, membrane proteins (10 g) were incubated with this enzyme (0.2 units) in the presence of Tris-HCl (150 mM; pH 8) and Triton X-100 (1.3%) at 37°C for 1 h after samples were denatured with SDS (0.375%, w/v) and 2-mercaptoethanol (75 mM) at 37°C for 15 min. Digested samples were immunoblotted as above.
For dual-fluorescence immunocytochemistry, transfected cells grown on coverslips were fixed with paraformaldehyde (4%) for 20 min and permeabilized with methanol (80%) (11) . After overnight incubation at 4°C with rabbit anti-CaR antiserum (21825A; 500 nM) plus either mouse anti-Grp78 (BiP) or rat anti-CD44 antiserum, cells were washed and incubated with fluorescein-conjugated and Texas Red-conjugated anti-IgG antibodies for 60 min at room temperature (3, 19) . After washing, cells on coverslips were mounted on glass slides using Gel Mount (Biomeda, Foster City, CA) and examined with a Leica TCS confocal microscope (Laboratory for Cell Imaging, San Francisco Department of Veterans Affairs Medical Center). Fluorescent images were obtained sequentially and stored in a microcomputer. Paired pseudocolored images and their overlays are presented.
Statistics-Differences between wt and mutant CaR responses were tested by analysis of variance with the F-test using Excel 98 (MicroSoft, Seattle, WA).
RESULTS

Signaling Properties and Expression of CaRs with Truncated
C-terminal Tails-To determine whether the C-terminal tail of the bovine parathyroid CaR plays a role in signal transduction, we constructed three truncated receptors, CaR-(1-866), CaR-(1-895), and CaR-(1-929), that retain 3, 32, or 66 of the 222 amino acids in the tail, respectively (Fig. 1a) . Truncated and wt CaRs were either stably or transiently expressed in HEK-293 cells, and PLC activation was assessed by total InsP accumulation in response to changes in [Ca 2ϩ ] o from 0.5 to 5.0 mM. In cells stably expressing wt CaRs, this increment in [Ca 2ϩ ] o increased InsP production by 24.5 Ϯ 2.8-fold (Fig. 1b) , not significantly different from the responses in cells expressing CaR-(1-929) (28.8 Ϯ 3.6-fold). In cells expressing CaR-(1-895), however, raising [Ca 2ϩ ] o from 0.5 to 5 mM increased InsPs by 10.7 Ϯ 1.7-fold. This response was Ϸ40% that of wt CaRexpressing cells and was confirmed in three independent cell lines tested (Fig. 1b) . In cells stably expressing CaR-(1-866) with only a three-amino acid tail, raising [Ca 2ϩ ] o from 0.5 to 30 mM failed to stimulate InsP production ( Fig. 1b and data not shown). These findings indicate that progressive truncation of the C-terminal tail of the CaR reduced the ability of the receptor to activate PLC.
To determine whether the dampened signaling of these stably expressed truncated receptors was due to reduced expression, we performed immunoblotting. Approximately 10-fold more membrane protein from cells expressing CaR-(1-895) was required to produce a signal comparable with that of cells stably expressing wt CaRs (Fig. 1c) . The level of expression of the CaR-(1-866) in HEK-293 cells was significantly higher than that of CaR-(1-895) (Fig. 1c) . This was confirmed in two additional cell lines we generated and suggested that the inability of this mutant to activate PLC was not due to deficient receptor synthesis.
To address whether the above properties of truncated CaRs were in some way due to stable transfections, we compared these results to those from transiently transfected cells. High [Ca 2ϩ ] o -induced InsP responses in HEK-293 cells transiently expressing CaR-(1-895) were comparable with those of the wt CaR (Fig. 1d) . As predicted, the expression levels of this mutant receptor were also comparable with those of the wt CaR (Fig. 1e) . High [Ca 2ϩ ] o , however, also failed to increase InsP production in cells transiently expressing CaR-(1-866). The level of expression of CaR-(1-866) in these experiments was comparable with the wt CaR (Fig. 1e) . In contrast to CaR-(1-895), the level of expression of the severely truncated mutant CaR-(1-866) was similar to that of wt CaRs in both transient and stable transfections.
Immunoblots showed the expected differences in size between wt and truncated CaRs as follows: wt CaR Ͼ CaR-(1-929) Ͼ CaR-(1-895) Ͼ CaR-(1-866) (Fig. 1, c and e) . In both stably and transiently transfected cells expressing these cDNAs, two predominant glycosylated receptor forms as well as larger, likely aggregated receptors (Ͼ205 kDa) were evident (Fig. 1e) . The expression pattern of CaR-(1-866) in stably transfected cells differed somewhat from that of transiently transfected cells. Although the Ϸ100-kDa protein was observed in both systems (Fig. 1, c and e) , a 125-kDa band was seen only in transiently transfected cells (Fig. 1e) , suggesting that posttranslational modifications of this mutant receptor might differ as a result of variations in expression levels or receptor processing. This was confirmed in two immunoblots from two different membrane preparations.
To determine whether these truncated receptors were efficiently targeted to the membrane, we used confocal immunomicroscopy. In transiently transfected HEK-293 cells, CaR-(1-866), CaR-(1-895), and CaR-(1-929) were strongly localized to the membrane (Fig. 1f, green) and co-localized extensively with the hyaluronic acid receptor CD44, which serves as a cellsurface marker (17) (18) (Fig. 1f, red) . This was evident with the overlay of images (Fig. 1f, yellow) . Thus, the signaling defects of CaR-(1-866) were clearly not the result of the inability of this receptor to be inserted into the membrane. Tail non-Ala residues were substituted with Ala, initially in the context of CaR-(1-895) (Fig. 2a) . When these receptors were transiently expressed in HEK-293 cells, their ability to increase InsP production varied (Fig. 2b) . The two most striking mutants (Ala 879 -883 CaR-(1-895) and Ala 892-895 CaR-(1-895)) had at least a 50% reduction in their responses to a 4.5 mM increment in [Ca 2ϩ ] o (asterisks, Fig. 2, a and b) . Their InsP responses were only 3.1 Ϯ 0.4-and 2.8 Ϯ 0.1-fold, respectively. This was 40 -45% of the response in cells expressing CaR-(1-895) (7.1 Ϯ 0.4-fold increase) (Fig. 2b) . These findings indicate that mutating residues in these two regions significantly blocked the signaling ability of CaR-(1-895).
Signaling Properties and Expression of CaRs with TA or Single-site Mutations in the C-terminal
We next examined the expression of these TA CaR mutants by immunoblotting (Fig. 2c) . Whereas the lower Ϸ110-kDa bands in CaR-(1-895) and the seven TA mutants were reduced in intensity, compared with the lower band (Ϸ140 kDa) in the wt CaR, the intensity of this band was in fact greatest in membrane fractions from cells expressing Ala 879 -883 CaR-(1-895) and Ala 892-895 CaR-(1-895) (Fig. 2c, lanes 5 and 8) . The intensity of the upper band (Ϸ140 kDa) in membrane fractions from Ala 879 -883 CaR-(1-895) and Ala 892-895 CaR-(1-895) mutant expressing cells was greater than in CaR-(1-895) (Fig. 2c,  lanes 5 and 8 versus 1) . Thus, it is unlikely that the signaling defects we observed in these two TA mutants are due to defective receptor synthesis.
To determine which residue(s) in these regions are responsible for reduced signaling through PLC, we engineered these TA mutants in the context of the full-length CaR. Surprisingly, in cells expressing Ala 892-895 CaR, raising [Ca 2ϩ ] o from 0.5 to 5.0 mM increased InsP production by 12.6 Ϯ 1.3-fold (Fig. 3a) . This was twice the response in cells expressing wt CaRs (6.0 Ϯ 0.4-fold) in four experiments. The expression of Ala 892-895 CaR was comparable with that of wt CaR (Fig. 3b) . Therefore, these sites were not examined further. In contrast, in cells expressing Ala 879 -883 CaR, the ability of high [Ca 2ϩ ] o to increase InsPs was completely blocked (Fig. 3a) , suggesting that residues 879 -883 were required for efficient PLC activation. Because the expression level of Ala 879 -883 CaR was comparable with that of the wt CaR (Fig. 3b) (Fig. 4b) . Levels of receptor expression for the wt and these mutant CaRs in crude membrane fractions were similar by immunoblotting and possibly even greater in cells expressing Phe 882 3 Ala CaRs and Lys 883 3 Ala CaRs (Fig. 4c ). This suggested that the signaling defects of the His 880 3 Ala and Phe 882 3 Ala CaR mutants were not due to inadequate receptor synthesis.
Glycosylation of CaR Mutants-CaRs are known to undergo post-translational modifications such as glycosylation that are required for efficient processing and eventually cell-surface expression (24) . To test the possibility that alterations in glycosylation are responsible for the blunted PLC responses in CaR mutant-expressing cells, we examined the glycosylation patterns of wt and mutant CaRs. Membrane proteins from cells expressing these receptors were digested with PNG-F and Endo-H. Endo-H, which removes mannose from glycoproteins, reduced the size of the 140-kDa form of the CaR to Ϸ120 kDa but had no effect on the 160-kDa band (Fig. 5 ). An 80-kDa band, which reacted with anti-CaR antiserum, was also observed in the membrane proteins treated with Endo-H. Because the size of this band was significantly smaller than the predicted size of the CaR core protein, we speculate that it represents a degraded form of the CaR due to enzyme treatment. Digestion with PNG-F, which removes all N-linked carbohydrates, reduced the sizes of both the 140-and 160-kDa bands to Ϸ120 kDa (Fig. 5) as previously observed (12, 23) . In cells transfected with Ala 879 -883 CaR, His 880 3 Ala CaR, and Phe 882 3 Ala CaR cDNAs, both the 140-and 160-kDa forms of these receptors were present at levels comparable with those in cells expressing wt CaRs (Fig. 5) . Both glycosylated forms of these mutant receptors were also sensitive to PNG-F digestion, and only the 140-kDa receptor was digested by Endo-H (Fig. 5) . These results suggest that mutations at these sites do not change the glycosylation of CaRs, reflected by glycosidase sensitivity, and confirm the findings of Ray et al. ing wt CaR cDNA, receptors were detected in the membrane (Fig. 6, green) . These receptors co-localized with CD44 (Fig. 6,  red) as demonstrated by the overlay of signals yielding a yellow color. Levels of CD44 surface staining were equivalent in cells transfected with wt CaR, Ala 879 -883 CaR, His 880 3 Ala CaR, and Phe 882 3 Ala CaR cDNAs (Fig. 6, red) . A large portion of the mutant CaR proteins, in contrast to wt CaRs, was, however, localized to intracellular compartments that lacked CD44 staining (Fig. 6) . Only a small proportion of total cellular CaR staining in cells expressing these mutants was present in the membrane. The minimal degree of overlapping signals argues against significant co-localization of CaR protein and CD44 in cells expressing these three mutants. These findings support the idea that the reduced ability of these mutant receptors to activate PLC is due to diminished cell-surface expression.
To localize further the intracellular compartments in which these mutant receptors reside, we performed immunocytochemistry using the ER marker BiP or Grp78 (25) . In HEK-293 cells transfected with wt CaR cDNA, BiP staining was distributed predominantly in a punctate and in some areas in a mesh-like pattern. There was very little overlap with cellsurface staining of CaRs or staining in submembrane vesicles (Fig. 7, top panels) . On the other hand, in cells expressing Ala 879 -883 CaR, His 880 3 Ala CaRs, or Phe 882 3 Ala CaRs, the majority of CaR staining was intracellular. Much of it colocalized with BiP (Fig. 7) . This confirmed the intracellular retention of these mutant CaRs. Thus, it appears likely that mutating His 880 and Phe 882 either interferes with protein folding and or blocks CaR trafficking to the cell surface. DISCUSSION These studies suggest that a large portion of the C-terminal tail of the CaR is not required for PLC activation. The truncated receptors CaR-(1-929) and CaR-(1-895), expressed at levels comparable with the wt CaR, retain the ability to signal through PLC comparable with wt CaRs. This is consistent with a previous report (12) that deleting amino acids beyond residues 887 in the human CaR (compared with 888 in bovine parathyroid CaR) does not affect the ability of the receptor to activate PLC. We further found that deleting amino acids 867-895 in the C-terminal tail of the CaR completely blocked the ability of this truncated receptor to mediate high [Ca 2ϩ ] o -induced PLC responses despite strong membrane CaR expression. This suggested that important signaling determinants are present in this region of the CaR. Indeed, TA and single-site mutagenesis identified two amino acids, His 880 and Phe 882 , that turned out to be critical for efficient cell-surface expression of the full-length CaR and ultimately its ability to activate PLC maximally with the appropriate sensitivity to Ca 2ϩ . Mutating these residues to Ala caused significant intracellular retention of CaRs in transfected cells and reduced the ability of high [Ca 2ϩ ] o to stimulate PLC activity. Co-localization of these mutant receptors with the ER marker BiP suggested that their intracellular retention is likely due to defective receptor trafficking to the cell surface or enhanced degradation within cells.
BiP, a 78-kDa protein, is transiently associated with newly synthesized secretory and membrane proteins in the ER (25) . It binds to improperly folded, incompletely glycosylated, or mutated proteins and prevents their trafficking (26 -30) . It is likely that mutating His 880 and Phe 882 caused the intracellular retention of the resulting receptor proteins either by interrupting their folding or glycosylation. The glycosylation patterns of these mutant CaRs and their sensitivity to digestion by Endo-H and PNG-F, however, were indistinguishable from wt CaRs, suggesting that altered glycosylation does not explain the intracellular trapping of these mutants. These mutations, therefore, likely altered the conformation or folding of the resulting receptors.
Mutating amino acids in the C-terminal tail of the CaR may also block the interactions of receptor proteins with downstream signaling molecules. In cells expressing Ala 879 -883 CaRs, high [Ca 2ϩ ] o was unable to increase InsP production, despite the presence of receptors on the cell surface. Ray et al. (12) showed that mutating residues 875-879 to Ala in the human CaR (equivalent to residues from 876 -880 in the bovine parathyroid CaR) also blocked high [Ca 2ϩ ] o -induced PLC activation. This was seen even after levels of surface expression of the mutant receptors were adjusted to that of the wt CaR by increasing the quantity of cDNA transfected (12) . Thus, these mutants are intrinsically unable to interact with signaling molecules, even when their cell-surface expression is deliberately increased.
Interestingly, in cells expressing the single-site mutants His 880 3 Ala CaR and Phe 882 3 Ala CaR, high [Ca 2ϩ ] o increased InsP production to levels 30 -50% of the responses of wt CaRs, despite profound intracellular retention of these receptors and decreased cell-surface receptor expression. Whereas mutating these two sites individually appeared to alter the folding or secondary structure sufficiently to cause retention of these receptors, these mutations were not sufficient to block the receptor's interactions with signaling molecules that likely require other residues. When multiple sites were mutated in tandem, as in Ala 879 -883 CaR, coupling to downstream effectors was more dramatically impaired.
To examine whether a specific secondary structure is present between residues 866 and 895 and required for the function of the CaR, we did computer modeling using the Chou-Fasman method (31) . As illustrated in Fig. 8 , amino acids 877-891 in the CaR are predicted to adopt an ␣-helical structure that includes His 880 and Phe 882 . Substitutions of these residues with Ala do not affect the potential formation of this helical structure, according to the predictions by computer modeling (data not shown). Our findings suggest, however, that the specific functional groups in these His and Phe residues are required for the receptor to function properly, even in the presence of a putative ␣-helix. Our observations with the truncated receptor (CaR-(1-866) ) and studies of similarly truncated receptors by others (12, 13) indicate that deleting the region containing this putative ␣-helix produces receptors that are unable to activate PLC but that are not retained intracellularly. Studies with human CaRs, truncated at residue 865 (866 in the bovine parathyroid CaR), indicate that these receptors are normally glycosylated (12) . This further supports the idea that the inability of CaR-(1-866) to activate PLC is not likely to be due to improper glycosylation. ] o compared with wt CaRs. In the context of the full-length CaR, however, only the Ala 879 -883 CaR showed reduced signaling. Surprisingly, the reduced PLC activation due to mutating residues 879 -883 to Ala was greater in the context of the wt CaR (Ͼ95% inhibition) than in the context of CaR-(1-895) (Ϸ55% inhibition). This suggests that there may be inhibitory or modulatory domains in the full-length CaR beyond residue 895 that interact with residues closer to the membrane. In addition, why mutating residues 892-895 in the context of the truncated CaR-(1-895) blocked high [Ca 2ϩ ] o -induced signal transduction but had no effect when the same mutation was made in the context of wt CaR remains unclear. It is likely that multiple as yet unknown and important regulatory domains exist in residues beyond 895 in the CaR tail that are involved in modulating receptor function.
Naturally occurring mutations in the C-terminal tail of the CaR in FHH, NSHPT, and autosomal dominant hypocalcemia (13, 15) confirm the importance of this receptor domain in physiologic functions. Patients with FHH or NSHPT have increased serum Ca 2ϩ and PTH levels, due to a reduced ability of high [Ca 2ϩ ] o to suppress PTH secretion. In one kindred, an Alu-repetitive element is inserted after residue 876 (comparable with 877 in the bovine CaR) in the C-terminal tail. This causes premature termination of the CaR protein. As a result, the ability of the receptor to mobilize intracellular Ca 2ϩ is markedly suppressed (to Ͻ10% of wt control) (13) , despite adequate cell-surface expression. This supports our hypothesis that deleting the putative ␣-helical domain in the region between 877 and 891 interferes with signaling by the CaR.
In another kindred with FHH, a Phe 3 Leu mutation at residue 881 of the CaR (Phe 882 in the bovine CaR) causes reduced CaR-dependent mobilization of intracellular Ca 2ϩ and shifts the ED 50 value of the receptor to the right (15 . This deletion mutant, expressed in HEK-293 cells, shows increased levels of membrane CaR expression, suggesting a "dominant positive" effect of the loss of this portion of the CaR tail on expression (16) . Taken together, available in vitro data on the CaR tail mutants plus information on naturally occurring human CaR mutations in this region underscore the multiple functions served by the CaR tail in extracellular Ca 2ϩ sensing in vivo.
